Clinical Trials Browser

Docetaxel × Thoracic × Clear all

NCT05450692 2026-04-16

LATIFY

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01630733 2026-04-15

ENSPIRIT

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT05616624 2026-04-15

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT05910827 2026-04-15

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Phase 1/2 Recruiting

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT06745908 2026-04-15

ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04928846 2026-04-14

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05142189 2026-04-14

LuCa-MERIT-1

Phase 1 Recruiting

EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT05671510 2026-04-14

PRESERVE-003

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07528274 2026-04-14

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04310007 2026-04-13

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Lung Neoplasms

NCT04895709 2026-04-13

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06382129 2026-04-13

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06532032 2026-04-13

swalloWTail

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06928389 2026-04-09

NSCLC

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06635824 2026-04-08

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Phase 3 Active not recruiting

Lung Neoplasms

NCT06632327 2026-04-07

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT03158129 2026-04-06

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Phase 2 Completed

101 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT07001618 2026-04-03

IMMUNOLIFE2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06472245 2026-04-01

ARTEMIA

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06780098 2026-04-01

MK-3475-01I

Phase 2 Recruiting

Lung Neoplasms

NCT05094336 2026-03-31

MTAPESTRY 101

Phase 1/2 Active not recruiting

CNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioma, Stomach Neoplasms

NCT06120075 2026-03-31

ARC-27

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06868732 2026-03-30

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Phase 1 Recruiting

Advanced Non-small Cell Lung Cancer

NCT04303780 2026-03-27

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Phase 3 Active not recruiting

345 enrolled 11 charts

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

NCT04656652 2026-03-24

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Phase 3 Active not recruiting

605 enrolled 14 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT07291037 2026-03-20

TROPION-Lung17

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT02973789 2026-03-18

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

Phase 3 Completed

291 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT06012435 2026-03-18

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT05633667 2026-03-17

VELOCITY-Lung

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT06841055 2026-03-13

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06881784 2026-03-12

RASolve 301

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07464327 2026-03-11

A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07459751 2026-03-10

A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Phase 2/3 Not yet recruiting

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

NCT03178552 2026-03-09

B-FAST

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05904379 2026-03-09

AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

Advanced Non-small-cell Lung Cancer

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT02642042 2026-03-04

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Phase 2 Active not recruiting

60 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT07246863 2026-03-04

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Phase 2 Recruiting

Other solid neoplasmThoracic

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT07442565 2026-03-04

SYNSTAR03

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05378763 2026-02-18

PINNACLE

Phase 3 Suspended

NSCLC

NCT07416994 2026-02-18

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06074588 2026-02-13

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03611738 2026-02-09

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04884282 2026-02-06

COMBI-TED

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02486718 2026-02-05

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Phase 3 Active not recruiting

1,280 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04340882 2026-01-30

DoceRamPem

Phase 2 Active not recruiting

Lung Neoplasms

NCT06484491 2026-01-30

HyDose

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05500092 2026-01-28

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT06266299 2026-01-28

A Study of KK2269 in Adult Participants With Solid Tumors

Phase 1 Recruiting

GastrointestinalThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis